Consolidated Statement of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2021 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2020	$ 1	$ 48,453	$ (48,551)	$ (856)	$ (953)
Beginning Balance (Shares) at Dec. 31, 2020	111,429,532
Other comprehensive income				(516)	(516)
Issuance of shares to atai Life Sciences (net of transaction costs of $297)		8,398			8,398
Issuance of shares to atai Life Sciences (net of transaction costs of $297) (shares)	37,300,000
Issuance of warrants to atai Life Sciences (net of transaction costs of $125)		3,526			3,526
Agents' warrants issued		164			164
Conversion of convertible notes		321			321
Conversion of convertible notes (in shares)	1,048,229
Conversion of convertible debentures		321			321
Conversion of convertible debentures (in shares)	850,000
Stock-based compensation		81			81
Beneficial conversion feature, net of a deferred income tax liability of $86		325			325
Net loss for the period			(6,454)		(6,454)
Ending Balance at Sep. 30, 2021	$ 1	$ 61,589	$ (55,005)	$ (1,372)	$ 5,213
Ending Balance (Shares) at Sep. 30, 2021	150,627,761